> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Corium Patch for Alzheimer’s
- URL: https://www.fdaweb.com/fda-approves-corium-patch-for-alzheimers/
- Published: 2022-03-18T12:00:00.000Z
- Updated: 2026-09-14T17:37:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151405

FDA has approved Corium’s Adlarity (donepezil transdermal system) to treat patients with mild, moderate, or severe dementia of the Alzheimer’s type. The company [says](https://corium.com/pdf/Corium-FDA-ADLARITY-Approval-Press-Release.pdf?ref=fdaweb.com) it is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin, resulting in a low likelihood of adverse gastrointestinal side effects associated with oral donepezil. Adlarity also is the first approved prescription drug product using Corium’s proprietary Corplex transdermal technology, the company says.

Corium says donepezil is the most prescribed medication in a class of Alzheimer’s drugs known as acetylcholinesterase inhibitors and is the active ingredient in oral Aricept. “The availability of a once-weekly patch formulation of donepezil has the potential to substantially benefit patients, caregivers, and healthcare providers,” says Banner Alzheimer’s Institute director **Pierre Tariot**. “It offers effective, well-tolerated, and stable dosing for seven days for patients who cannot take daily oral donepezil reliably because of impaired memory. It can also offer benefits for those patients who have diminished ability to swallow or have GI side effects associated with ingestion of oral donepezil.”